Rebus Holdings, Inc. (RBSH)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 5.24 Million USD | -8.63% |
| 2021 | 5.73 Million USD | -55.55% |
| 2020 | 12.9 Million USD | 47.58% |
| 2019 | 8.74 Million USD | 1.31% |
| 2018 | 8.63 Million USD | -3.18% |
| 2017 | 8.91 Million USD | 114.2% |
| 2016 | 4.16 Million USD | -9.22% |
| 2015 | 4.58 Million USD | 81.12% |
| 2014 | 2.53 Million USD | -3.54% |
| 2013 | 2.62 Million USD | -20.48% |
| 2012 | 3.3 Million USD | 25.15% |
| 2011 | 2.63 Million USD | 2.61% |
| 2010 | 2.57 Million USD | 3.57% |
| 2009 | 2.48 Million USD | 349.82% |
| 2008 | 551.77 Thousand USD | 217.7% |
| 2007 | 173.67 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 5.61 Million USD | -0.76% |
| 2023 Q1 | 5.66 Million USD | 8.01% |
| 2022 FY | 5.24 Million USD | -8.63% |
| 2022 Q3 | 6.02 Million USD | -6.91% |
| 2022 Q4 | 5.24 Million USD | -12.94% |
| 2022 Q2 | 6.46 Million USD | 19.18% |
| 2022 Q1 | 5.42 Million USD | -5.4% |
| 2021 Q1 | 30.09 Million USD | 133.18% |
| 2021 FY | 5.73 Million USD | -55.55% |
| 2021 Q2 | 13.08 Million USD | -56.54% |
| 2021 Q3 | 6.31 Million USD | -51.72% |
| 2021 Q4 | 5.73 Million USD | -9.15% |
| 2020 Q3 | 7.24 Million USD | -27.58% |
| 2020 FY | 12.9 Million USD | 47.58% |
| 2020 Q1 | 8.86 Million USD | 1.37% |
| 2020 Q2 | 10 Million USD | 12.85% |
| 2020 Q4 | 12.9 Million USD | 78.13% |
| 2019 Q2 | 9.11 Million USD | 9.44% |
| 2019 Q4 | 8.74 Million USD | 2.85% |
| 2019 Q3 | 8.5 Million USD | -6.65% |
| 2019 Q1 | 8.32 Million USD | -3.58% |
| 2019 FY | 8.74 Million USD | 1.31% |
| 2018 Q2 | 8.21 Million USD | -8.83% |
| 2018 FY | 8.63 Million USD | -3.18% |
| 2018 Q4 | 8.63 Million USD | -22.8% |
| 2018 Q3 | 11.18 Million USD | 36.05% |
| 2018 Q1 | 9.01 Million USD | 1.1% |
| 2017 Q4 | 8.91 Million USD | 3.27% |
| 2017 Q3 | 8.63 Million USD | 90.28% |
| 2017 Q2 | 4.53 Million USD | 8.43% |
| 2017 FY | 8.91 Million USD | 114.2% |
| 2017 Q1 | 4.18 Million USD | 0.53% |
| 2016 Q3 | 4.57 Million USD | 16.43% |
| 2016 Q1 | 4.14 Million USD | -9.66% |
| 2016 FY | 4.16 Million USD | -9.22% |
| 2016 Q2 | 3.93 Million USD | -5.07% |
| 2016 Q4 | 4.16 Million USD | -9.08% |
| 2015 Q2 | 3.13 Million USD | 3.67% |
| 2015 Q1 | 3.02 Million USD | 19.55% |
| 2015 FY | 4.58 Million USD | 81.12% |
| 2015 Q4 | 4.58 Million USD | 38.51% |
| 2015 Q3 | 3.31 Million USD | 5.51% |
| 2014 Q1 | 2.23 Million USD | -14.93% |
| 2014 Q3 | 2.53 Million USD | 12.45% |
| 2014 Q4 | 2.53 Million USD | -0.24% |
| 2014 Q2 | 2.25 Million USD | 1.07% |
| 2014 FY | 2.53 Million USD | -3.54% |
| 2013 FY | 2.62 Million USD | -20.48% |
| 2013 Q3 | 1.94 Million USD | -15.25% |
| 2013 Q2 | 2.29 Million USD | -10.67% |
| 2013 Q1 | 2.56 Million USD | -22.18% |
| 2013 Q4 | 2.62 Million USD | 34.96% |
| 2012 Q3 | 3.25 Million USD | 3.89% |
| 2012 Q1 | 3.38 Million USD | 28.44% |
| 2012 FY | 3.3 Million USD | 25.15% |
| 2012 Q4 | 3.3 Million USD | 1.5% |
| 2012 Q2 | 3.13 Million USD | -7.59% |
| 2011 Q1 | 2.2 Million USD | -14.26% |
| 2011 Q2 | 2.67 Million USD | 21.3% |
| 2011 FY | 2.63 Million USD | 2.61% |
| 2011 Q4 | 2.63 Million USD | 11.38% |
| 2011 Q3 | 2.36 Million USD | -11.42% |
| 2010 FY | 2.57 Million USD | 3.57% |
| 2010 Q4 | 2.57 Million USD | 21.36% |
| 2010 Q1 | 4 Million USD | 61.23% |
| 2010 Q2 | 3.08 Million USD | -22.95% |
| 2010 Q3 | 2.11 Million USD | -31.29% |
| 2009 FY | 2.48 Million USD | 349.82% |
| 2009 Q2 | 2.45 Million USD | 12.16% |
| 2009 Q4 | 2.48 Million USD | 2.69% |
| 2009 Q3 | 2.41 Million USD | -1.41% |
| 2009 Q1 | 2.18 Million USD | 296.14% |
| 2008 FY | 551.77 Thousand USD | 217.7% |
| 2008 Q4 | 551.77 Thousand USD | 0.0% |
| 2007 FY | 173.67 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -19008.373% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 44.622% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 92.767% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -548.125% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 91.117% |
| Qrons Inc. | 1.48 Million USD | -252.116% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -327.495% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 93.003% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -11628.119% |
| Skye Bioscience, Inc. | 14.07 Million USD | 62.749% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 90.166% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 45.293% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1143.453% |
| SQZ Biotechnologies Company | 50.03 Million USD | 89.524% |
| Intellipharmaceutics International Inc. | 12 Million USD | 56.349% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -36.106% |
| Mesoblast Limited | 188.44 Million USD | 97.218% |
| Marizyme, Inc. | 26.67 Million USD | 80.349% |
| Genus plc | 485 Million USD | 98.919% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 10.28% |
| Pharming Group N.V. | 244.07 Million USD | 97.852% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -160.779% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -108.319% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -37.947% |
| ContraFect Corporation | 32.53 Million USD | 83.886% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -164.573% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -36.951% |
| IMV Inc. | 37.93 Million USD | 86.181% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 55.494% |
| MultiCell Technologies, Inc. | 1617.67 USD | -323946.314% |
| ONE Bio Corp. | 27.49 Million USD | 80.935% |
| Accustem Sciences Inc. | 1.07 Million USD | -385.713% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 93.229% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -147.841% |
| Q BioMed Inc. | 8.13 Million USD | 35.546% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 93.679% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -1.865% |
| Biomind Labs Inc. | 1.49 Million USD | -249.79% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 95.585% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 42.027% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 71.516% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -265.586% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3589.081% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2506.456% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 8.768% |
| GB Sciences, Inc. | 5.41 Million USD | 3.241% |
| Alpha Cognition Inc. | 7.16 Million USD | 26.836% |
| HST Global, Inc. | 593.59 Thousand USD | -783.097% |
| CSL Limited | 18.62 Billion USD | 99.972% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -316.298% |
| Halberd Corporation | 728.71 Thousand USD | -619.344% |
| Enzolytics Inc. | 365.26 Million USD | 98.565% |
| Agentix Corp. | 2.51 Million USD | -108.798% |
| Resverlogix Corp. | 67.39 Million USD | 92.222% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -524.991% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.822% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -205.834% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 78.817% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 55.961% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -43.022% |
| AVAX Technologies, Inc. | 3.99 Million USD | -31.255% |
| Zenith Capital Corp. | 27.56 Thousand USD | -18914.11% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.605% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2096.485% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -40.374% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -669.938% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -93.315% |
| Kadimastem Ltd | 3.5 Million USD | -49.563% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -7732.18% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 89.571% |
| BioStem Technologies, Inc. | 15.9 Million USD | 67.041% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1028.042% |
| LadRx Corporation | 2.2 Million USD | -138.216% |
| Cell Source, Inc. | 15.8 Million USD | 66.837% |
| Regen BioPharma, Inc. | 5.45 Million USD | 3.951% |
| Regen BioPharma, Inc. | 5.45 Million USD | 3.951% |
| NovAccess Global Inc. | 7.86 Million USD | 33.314% |
| Affymax, Inc. | 8.87 Million USD | 40.909% |
| Itoco Inc. | 1.65 Million USD | -217.091% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -155.512% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 13.341% |
| Mobile Lads Corp. | 1.31 Million USD | -299.087% |
| CytoDyn Inc. | 127.89 Million USD | 95.901% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -12440.97% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -234.658% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 52.541% |
| SYBLEU INC | 681.41 Thousand USD | -669.284% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 14.092% |
| International Stem Cell Corporation | 5.27 Million USD | 0.663% |
| Bioxytran, Inc. | 3.24 Million USD | -61.317% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -737.636% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -13.534% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 87.213% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 76.456% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -158.815% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 4.308% |
| Neutra Corp. | 973.52 Thousand USD | -438.453% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 81.933% |
| PureTech Health plc | 125.58 Million USD | 95.826% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -39.522% |
| IXICO plc | 1.9 Million USD | -175.852% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 74.465% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.927% |
| CSL Limited | 18.62 Billion USD | 99.972% |
| Cellectis S.A. | 249.36 Million USD | 97.898% |